/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Adverum Biotechnologies Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.22 0.0024(0.24%) ADVM at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 4.16
Highest Today 4.185
Today’s Open 4.17
Prev. Close 4.16
52 Week High 6.12
52 Week Low 1.78
Day’s Range: Low 4.16 High 4.185
52-Week Range: Low 1.78 High 6.12
1 day return -
1 Week return +1.21
1 month return -2.79
3 month return +30.21
6 month return +69.23
1 year return -30.56
3 year return -36.65
5 year return -96.95
10 year return -

Institutional Holdings

BML Capital Management LLC 14.57

TCG Crossover Management, LLC 8.56

Principia Wealth Advisory, LLC 8.09

Vanguard Group Inc 4.21

Vanguard Total Stock Mkt Idx Inv 2.73

Renaissance Technologies Corp 2.72

5AM Venture Management, LLC 2.58

Goldman Sachs Group Inc 2.37

BlackRock Inc 1.98

Pale Fire Capital SE 1.71

Millennium Management LLC 1.63

Soleus Capital Management, L.P. 1.37

Dimensional Fund Advisors, Inc. 1.36

Vanguard Institutional Extnd Mkt Idx Tr 0.94

Geode Capital Management, LLC 0.88

Regeneron Pharmaceuticals Inc 0.86

Warren Averett Asset Management, LLC 0.77

Grant/GrossMendelsohn, LLC() 0.76

Fidelity Extended Market Index 0.42

Citadel Advisors Llc 0.37

Jane Street Group LLC 0.34

Galileo - Biotech Innovation Fund S USD 0.33

State Street Corp 0.33

Readystate Asset Management LP 0.32

Dimensional US Targeted Value ETF 0.21

DFA US Small Cap I 0.21

Dimensional US Small Cap ETF 0.20

Extended Equity Market Fund K 0.19

iShares Micro-Cap ETF 0.17

DFA US Micro Cap I 0.15

Fidelity Total Market Index 0.14

DFA US Targeted Value I 0.12

Fidelity Series Total Market Index 0.11

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.11

Goldman Sachs Absolute Ret Trckr Instl 0.10

Spartan Extended Market Index Pool F 0.09

DFA US Core Equity 2 I 0.09

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

NT Ext Equity Mkt Idx Fd - NL 0.07

Market Status

Strong Buy: 5

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 91.84 M

PB Ratio 0.9297

PE Ratio 0.0

Enterprise Value 153.84 M

Total Assets 179.84 M

Volume 464324

Company Financials

Annual Revenue FY23:3600000 3.6M, FY22:0 0.0M, FY21:7500000 7.5M, FY20:0 0.0M, FY19:250000 0.3M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:7500000 7.5M, FY20:null 0.0M, FY19:250000 0.3M

Annual Net worth FY23:-126187000 -126.2M, FY22:-154536000 -154.5M, FY21:-145540000 -145.5M, FY20:-117507000 -117.5M, FY19:-64486000 -64.5M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:-3600000 -3.6M, Q3/2024:1000000 1.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-465000 -0.5M, Q2/2025:-535000 -0.5M, Q1/2025:-683000 -0.7M, Q3/2024:110000 0.1M, Q2/2024:-956000 -1.0M

Quarterly Net worth Q3/2025:-47652000 -47.7M, Q2/2025:-49191000 -49.2M, Q1/2025:-47019000 -47.0M, Q3/2024:-27134000 -27.1M, Q2/2024:-18476000 -18.5M

Fund house & investment objective

Company Information Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Organisation Biotechnology

Employees 155

Industry Biotechnology

CEO Dr. Laurent Fischer M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow